Trial · NCT01236547
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| (Phase II) Overall Survival | (Phase II) Pazopanib, Paclitaxel, IMRT | 37.1 | 95% Confidence Interval 21.1 to 53.2 | percentage of participants | |
| (Phase II) Overall Survival | (Phase II) Placebo, Paclitaxel, IMRT | 29.0 | 95% Confidence Interval 13.2 to 44.8 | percentage of participants | |
(Phase I) Number of Participants With Treatment-related Grade 4 Hemorrhage, Grade 4 Febrile Neutropenia, or Grade 5 Adverse Event (AE), or Discontinuation of Treatment Due to Toxicity [Adverse Events of Concern (AEC)] | (Run-in 1) Pazopanib, Paclitaxel, IMRT | 0 | Participants | ||
(Phase I) Number of Participants With Treatment-related Grade 4 Hemorrhage, Grade 4 Febrile Neutropenia, or Grade 5 Adverse Event (AE), or Discontinuation of Treatment Due to Toxicity [Adverse Events of Concern (AEC)] | (Run-in 2) Pazopanib, Paclitaxil, IMRT | 0 | Participants | ||
(Phase I) Number of Participants With Treatment-related Grade 4 Hemorrhage, Grade 4 Febrile Neutropenia, or Grade 5 Adverse Event (AE), or Discontinuation of Treatment Due to Toxicity [Adverse Events of Concern (AEC)] | (Run-in 3) Pazopanib, Paclitaxel, IMRT | 2 | Participants | ||
(Phase I) Number of Participants With Treatment-related Grade 4 Hemorrhage, Grade 4 Febrile Neutropenia, or Grade 5 Adverse Event (AE), or Discontinuation of Treatment Due to Toxicity [Adverse Events of Concern (AEC)] | (Phase II) Pazopanib, Paclitaxel, IMRT | 0 | Participants | ||
| (Phase II) Local-regional Control | (Phase II) Pazopanib, Paclitaxel, IMRT | 6 months | 20.0 | 95% Confidence Interval 8.6 to 34.8 | percentage of participants |
| (Phase II) Local-regional Control | (Phase II) Placebo, Paclitaxel, IMRT | 6 months | 27.3 | 95% Confidence Interval 13.3 to 43.3 | percentage of participants |
| (Phase II) Local-regional Control | (Phase II) Pazopanib, Paclitaxel, IMRT | 1 year | 28.6 | 95% Confidence Interval 14.6 to 44.3 | percentage of participants |
| (Phase II) Local-regional Control | (Phase II) Placebo, Paclitaxel, IMRT | 1 year | 33.6 | 95% Confidence Interval 17.9 to 50.0 | percentage of participants |
(Phase II) Percentage of Participants With Treatment-related Grade 4 Hemorrhage, Grade 4 Febrile Neutropenia, or Grade 5 Adverse Event, or Discontinuation of Treatment Due to Toxicity [Adverse Events of Concern] | (Phase II) Pazopanib, Paclitaxel, IMRT | 2.8 | 95% Confidence Interval 0.1 to 14.5 | percentage of participants | |
(Phase II) Percentage of Participants With Treatment-related Grade 4 Hemorrhage, Grade 4 Febrile Neutropenia, or Grade 5 Adverse Event, or Discontinuation of Treatment Due to Toxicity [Adverse Events of Concern] | (Phase II) Placebo, Paclitaxel, IMRT | 11.8 | 95% Confidence Interval 3.3 to 27.5 | percentage of participants | |
| (Phase II) Percentage of Participants With Treatment-related Grade 3 or 4 Adverse Events Other Than Grade 4 Hemorrhage or Grade 4 Febrile Neutropenia [Not Adverse Events of Concern] | (Phase II) Pazopanib, Paclitaxel, IMRT | 86.1 | 95% Confidence Interval 70.5 to 95.3 | percentage of participants | |
| (Phase II) Percentage of Participants With Treatment-related Grade 3 or 4 Adverse Events Other Than Grade 4 Hemorrhage or Grade 4 Febrile Neutropenia [Not Adverse Events of Concern] | (Phase II) Placebo, Paclitaxel, IMRT | 85.3 | 95% Confidence Interval 68.9 to 95.0 | percentage of participants | |
| (Phase II) Percentage of Participants With Complete or Partial Response of the Primary Site After Chemoradiation Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | (Phase II) Pazopanib, Paclitaxel, IMRT | 30.4 | 95% Confidence Interval 13.2 to 52.9 | percentage of participants | |
| (Phase II) Percentage of Participants With Complete or Partial Response of the Primary Site After Chemoradiation Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | (Phase II) Placebo, Paclitaxel, IMRT | 33.3 | 95% Confidence Interval 16.5 to 54.0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01236547/results